Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.730
-0.490 (-9.39%)
Mar 31, 2025, 1:13 PM EDT - Market open
Verve Therapeutics Revenue
In the year 2024, Verve Therapeutics had annual revenue of $32.33M with 174.98% growth. Verve Therapeutics had revenue of $13.08M in the quarter ending December 31, 2024, with 154.28% growth.
Revenue (ttm)
$32.33M
Revenue Growth
+174.98%
P/S Ratio
13.68
Revenue / Employee
$118,000
Employees
274
Market Cap
420.00M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VERV News
- 7 days ago - Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - GlobeNewsWire
- 27 days ago - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation - Accesswire